Brief: Kiniksa Announces Positive Results For Mavrilimumab Phase 2 Trial In Non-Mechanically Ventilated Severe Covid-19 Patients

Kiniksa Pharmaceuticals International

12/04/2021 12:46

April 12 (Reuters) - Kiniksa Pharmaceuticals Ltd  KNSA.O :
    * KINIKSA ANNOUNCES POSITIVE RESULTS FOR MAVRILIMUMAB PHASE
2
TRIAL IN NON-MECHANICALLY VENTILATED SEVERE COVID-19 PATIENTS
    * KINIKSA PHARMACEUTICALS LTD - MAVRILIMUMAB WAS
WELL-TOLERATED
AND EXHIBITED A FAVORABLE SAFETY PROFILE
    * KINIKSA PHARMACEUTICALS LTD - ENROLLMENT IN PHASE 3
PORTION OF
TRIAL ONGOING
    * KINIKSA PHARMACEUTICALS LTD - CLINICAL IMPROVEMENT WAS
OBSERVED
ON TOP OF STEROIDS AND/OR ANTIVIRALS
    * KINIKSA PHARMACEUTICALS LTD - ACHIEVED ITS PRIMARY
EFFICACY
ENDPOINT OF PROPORTION OF PATIENTS ALIVE AND FREE OF MECHANICAL
VENTILATION AT DAY 29
    * KINIKSA PHARMACEUTICALS LTD - EXPECTS TO PROVIDE NEXT
STEPS FOR
BROADER MAVRILIMUMAB DEVELOPMENT PROGRAM THIS QUARTER

Source text for Eikon:  ID:nGNX6vzWY8 
Further company coverage:  KNSA.O 

 ((Reuters.Briefs@thomsonreuters.com;))